Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Lymphangioleiomyomatosis: a clinical review

Anne M. O'Mahony, Evelyn Lynn, David J. Murphy, Aurelie Fabre, Cormac McCarthy
Breathe 2020 16: 200007; DOI: 10.1183/20734735.0007-2020
Anne M. O'Mahony
1Dept of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland
5These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evelyn Lynn
1Dept of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland
5These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Murphy
2Dept of Radiology, St Vincent's University Hospital, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aurelie Fabre
3Dept of Histopathology, St Vincent's University Hospital, Dublin, Ireland
4School of Medicine, University College Dublin, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cormac McCarthy
1Dept of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland
4School of Medicine, University College Dublin, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cormac.mccarthy@ucd.ie
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    mTOR signalling pathways and sites of action of mTOR inhibitors. Two different complexes contain mTOR: mTORC1 (acutely sensitive to rapamycin) and mTORC2 (inhibited by rapamycin after prolonged exposure). The tuberin–hamartin complex acts as a regulator of protein synthesis and cell growth. Upstream signals such as growth factors, energy state and amino acids (AA) serve to regulate mTOR. The complex maintains Rheb (Ras homologue enriched in brain) in the guanosine diphosphate (GDP)-loaded state, thereby inhibiting mTORC1 function. Activation of mTORC1 leads to phosphorylation of S6 kinase 1 (S6K1), which is required for ribosome assembly and protein synthesis. Activation of mTORC2 results in phosphorylation of Akt, further promoting mTOR activity by inhibition of tuberin–hamartin. When activated, mTORC1 blocks further phosphorylation of Akt via a negative feedback loop. AMPK: AMP-dependent protein kinase; Raptor: regulatory associated protein of TOR; mLST8: mammalian lethal with SEC13 protein 8; PRR5: proline-rich protein 5; Rictor: rapamycin-insensitive companion of TOR; mSIN1: mammalian stress-activated protein kinase-interacting protein 1; 4E-BP1: factor 4E-binding protein 1.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Computed tomography (CT) Findings in LAM. a) Axial CT thorax in a 48-year-old woman demonstrates a small number of uniform thin-walled pulmonary cysts (arrows) with intervening normal lung parenchyma consistent with mild LAM. b) Axial CT of the lower thorax in a 41-year-old woman with LAM demonstrates a moderate number of relatively uniform pulmonary cysts. c) Axial CT thorax in a 36-year-old woman with severe LAM shows innumerable cysts throughout both lungs, with little intervening normal lung parenchyma visible.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    CT image of angiomyolipoma (AML). Coronal CT abdomen in a 48-year-old woman (figure 1a) demonstrates a 22-cm AML arising from the lower pole of the right kidney. Note the internal large vessels within the AML (arrows).

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    Lung biopsy in LAM. a) Lung parenchyma showing multiple cysts (arrows) with proliferation of b) spindle cells that are c) Human Melanoma Black 45 positive. Scale bars: a) 1000 μm; b and c) 100 μm.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5

    Diagnostic algorithm. #: features may include middle-aged female patients presenting with a pneumothorax, progressive dyspnoea or isolated low DLCO, patents with features of TSC (subungual fibromas and facial angiofibromas) or patients with chylous complications such as chylothorax, chylous ascites or lymphatic complications (lymphangioleiomyomas). ¶: characteristic features on CT include multiple, diffuse, round, thin-walled cysts in a uniform distribution, often devoid of internal structures. +: features such as subungual fibromas, facial angiofibromas, history of cognitive impairment or seizures; patients should be considered for referral to a centre that specialises in TSC. §: serum VEGF-D levels >800 pg·mL−1 in the presence of characteristic lung cysts on HRCT is associated with a specificity that approaches 100% for the diagnosis of LAM. ƒ: decision to undergo biopsy should be individualised; certain patients who are asymptomatic with only mild disease can undergo surveillance with serial PFTs every 3–6 months; however, all efforts to establish a diagnosis should be made if treatment with a mTOR inhibitor is planned. LN: lymphadenopathy. Reproduced and modified from [36] with permission from the publisher.

Tables

  • Figures
  • Table 1

    Prognostic factors in LAM

    Favourable prognosisPoor prognosis
    Older age at diagnosis [46]
    Post-menopausal status [19]
    FEV1 >70% pred at diagnosis [19]
    Progressive dyspnoea at presentation [47]
    Pre-menopausal status [19, 37, 44, 45]
    FEV1 <70% pred at diagnosis [20, 48]
    Reversible airflow obstruction [19, 49]
    Use of supplementary oxygen [19, 46]
    VEGF-D: high levels (>800 ng·mL−1) [18]
PreviousNext
Back to top
Vol 16 Issue 2 Table of Contents
Breathe: 16 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lymphangioleiomyomatosis: a clinical review
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Lymphangioleiomyomatosis: a clinical review
Anne M. O'Mahony, Evelyn Lynn, David J. Murphy, Aurelie Fabre, Cormac McCarthy
Breathe Jun 2020, 16 (2) 200007; DOI: 10.1183/20734735.0007-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Lymphangioleiomyomatosis: a clinical review
Anne M. O'Mahony, Evelyn Lynn, David J. Murphy, Aurelie Fabre, Cormac McCarthy
Breathe Jun 2020, 16 (2) 200007; DOI: 10.1183/20734735.0007-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Epidemiology
    • Pathophysiology
    • Clinical features
    • Diagnostic evaluation
    • Natural history
    • Prognostic factors
    • Management of LAM
    • Future Directions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Management of asthma during conception, pregnancy and delivery
  • Non-traumatic chylothorax: diagnostic and therapeutic strategies
  • Industry influence in healthcare harms patients: myth or maxim?
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2022 by the European Respiratory Society